SELLAS Life Sciences Group, Inc. — Director's Dealing 2010

Jul 16, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-07-15

Reporting Person: Pavco Pamela (VP of Pharmaceutical Devlpmt.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-07-15	Common Stock	A	5000	$2.3842	Acquired	11377	Direct

Footnotes

F1: The purchase price reported in this Form 4 was between the range of $2.36 per share and $2.39 per share. Full information regarding the number of shares purchased at each seperate price will be provided to the Commission staff upon request.